Compare PUBM & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | EOLS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 304.0M |
| IPO Year | 2020 | 2018 |
| Metric | PUBM | EOLS |
|---|---|---|
| Price | $8.28 | $4.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $18.44 | $17.40 |
| AVG Volume (30 Days) | ★ 791.0K | 686.0K |
| Earning Date | 05-29-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,926,000.00 | $266,274,000.00 |
| Revenue This Year | $0.85 | $13.57 |
| Revenue Next Year | $5.90 | $11.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 31.76 |
| 52 Week Low | $6.15 | $4.09 |
| 52 Week High | $13.26 | $14.60 |
| Indicator | PUBM | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 35.24 |
| Support Level | $7.97 | $4.09 |
| Resistance Level | $9.11 | $4.99 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 90.21 | 25.33 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.